Molecular analysis of multifocal papillary thyroid carcinoma

Journal of Molecular Endocrinology

Volumn 41, Issue 3-4, 2008, Pages 195-203

  Lin, Xiaoqi ^a   Finkelstein, Sydney D ^b   Zhu, Bing ^a   Silverman, Jan F ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Redpath Integrated Pathology Inc   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MOLECULAR MARKER; TUMOR MARKER;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER MORPHOLOGY; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MOLECULAR DYNAMICS; MULTIPLE CANCER; MUTATIONAL ANALYSIS; PAPILLARY CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME;

CARCINOMA, PAPILLARY; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 22; DNA MUTATIONAL ANALYSIS; GENETIC HETEROGENEITY; HUMANS; LOSS OF HETEROZYGOSITY; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 55749103843     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/JME-08-0063     Document Type: Article

References (73)

1. Akslen LA & Myking AO 1992 Differentiated thyroid carcinomas: the relevance of various pathological features for tumour classification and prediction of tumour progress. Virchows Archiv. A, Pathological Anatomy and Histopathology 421 17-23.
2. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A & Eng C 2004 Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. Journal of Clinical Oncology 22 3531-3539.
3. Alsanea O & Clark OH 2001 Familial thyroid cancer. Current Opinion in Oncology 13 44-51.
4. Alvarez-Nunez F, Bussaglia E, Mauricio D, Ybarra J, Vilar M, Lerma E, de Leiva A & Matias-Guiu X 2006 PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16 17-23.
5. Arem R, Padayatty SJ, Saliby AH & Sherman SI 1999 Thyroid microcarcinoma: prevalence, prognosis, and management. Endocrine Practice 5 148-156.
6. Attie JN, Khafif RA & Steckler RM 1971 Elective neck dissection in papillary carcinoma of the thyroid. American Journal of Surgery 122 464-471.
7. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, Cailleux AF, Lumbroso JD, Parmentier C & Schlumberger M 1998 Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 83 553-559.
8. Cady B, Sedgwick CE, Meissner WA, Bookwalter JR, Romagosa V & Werber J 1976 Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Annals of Surgery 184 541-553.
9. Castro P, Roque L, Magalhaes J & Sobrinho-Simoes M 2005 A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. International Journal of Surgical Pathology 13 235-238.
10. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL & El-Naggar AK 2004 Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clinical Cancer Research 10 6586-6597.
11. Chow SM, Law SC, Chan JK, Au SK, Yau S & Lau WH 2003 Papillary microcarcinoma of the thyroid - prognostic significance of lymph node metastasis and multifocality. Cancer 98 31-40.
12. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW & Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute 95 625-627.
13. David JM, Ruaux C, Bachaud JM, Bonnet F, Lucot H, Boneu A, Suc E & Cabarrot E 1992 Multiple localization and lymphatic involvement of papillary micro-carcinoma of the thyroid. Results of total thyroid-ectomy with bilateral lymph node excision. Apropos of 38 patients. Annales d'Oto-Laryngologie et de Chirurgie Cervico Faciale 109 183-187.
14. DeGroot LJ, Kaplan EL, McCormick M & Straus FH 1990 Natural history, treatment, and course of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 71 414-424.
15. Finley DJ, Lubitz CC, Wei C, Zhu B & Fahey TJ III 2005 Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid 15 562-568.
16. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collim P, Gariboldi M, Pilotti S et al. 2004 Alternative mutations of BRAF, RETand NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 7436-7440.
17. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S et al. 2006 Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-Related Cancer 13 455-464.
18. Harach HR, Franssila KO & Wasenius VM 1985 Occult papillary carcinoma of the thyroid. A 'normal' finding in Finland. A systematic autopsy study. Cancer 56 531-538.
19. Hunt JL, LiVolsi VA, Baloch ZW, Barnes EL, Swalsky PA, Niehouse L & Finkelstein SD 2003 Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss of heterozygosity mutational profile. American Journal of Pathology 27 159-166.
20. Kameyama K, Takami H, Miyajima K, Mimura T, Hosoda Y, Ito K & Ito K 2001 Papillary carcinoma occurring within an adenomatous goiter of the thyroid gland in Cowden's disease. Endocrine Pathology 12 73-76.
21. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B & Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery 246 466-470.
22. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ & Shong YK 2005 The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clinical Endocrinology 63 588-593.
23. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTGRAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457.
24. Kitamura Y, Shimizu K, Tanaka S, Ito K & Emi M 2000 Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma. Clinical Cancer Research 6 1819-1825.
25. Lee S, Hong SW, Shin SJ, Kim YM, Rhee Y, Jeon BI, Moon WC, Oh MR & Lim SK 2004 Papillary thyroid carcinoma associated with familial adenomatous polyposis: molecular analysis of pathogenesis in a family and review of the literature. Endocrine Journal 51 317-323.
26. Lin JD, Liou MJ, Chao TC, Weng HF & Ho YS 1999 Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases. Endocrine-Related Cancer 6 109-115.
27. Mazzaferri EL 1981 Papillary and follicular thyroid cancer: selective therapy. Comprehensive Therapy 7 6-14.
28. Mazzaferri EL & Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 97 418-428.
29. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT & Page CP 1977 Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 56 171-196.
30. McCarthy RP, Wang M, Jones TD, Strate RW & Cheng L 2006 Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clinical Cancer Research 12 2414-2418.
31. McConahey WM, Hay ID, Woolner LB, van Heerden JA & Taylor WF 1986 Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clinic Proceedings 61 978-996.
32. Mizukami Y, Noguchi M, Michigishi T, Nonomura A, Hashimoto T, Otakes S, Nakamura S & Matsubara F 1992 Papillary thyroid carcinoma in Kanazawa, Japan: prognostic significance of histological subtypes. Histapathology 20 243-250.
33. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M & Imada T 2007 Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Research 27 3645-3649.
34. Nemec J, Zamrazil V, Pohunkova D, Rolding S & Zeman V 1986 Some factors influencing the survival of patients with less advanced stages of differentiated thyroid cancer. Endocrinologia Experimentalis 20 85-95.
35. Noguchi S, Noguchi A & Murakami N 1970 Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer 26 1053-1060.
36. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y & de la Chapelle A 2004 CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 14 169-175.
37. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A & Giordano C 2007 BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid < or = 1 cm and their paired lymph node metastases. Cancer 110 1218-1226.
38. Rodriguez JM, Moreno A, Parrilla P, Sola J, Soria T, Tebar FJ & Aranda F 1997 Papillary thyroid microcarcinoma: clinical study and prognosis. European Journal of Surgery 163 255-259.
39. Rosai J, LiVolsi VA, Sobrinho-Simoes M & Williams ED 2003 Renaming papillary microcarcinoma of the thyroid gland: the Porto proposal. International Journal of Surgical Pathology 11 249-251.
40. Sakorafas GH, Giotakis J & Stafyla V 2005 Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treatment and Research 31 423-438.
41. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F et al. 2004 Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 89 5175-5180.
42. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, Lushnikov E, Kumagai A, Nakashima M, Meirmanov S et al. 2004 The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. International Journal of Oncology 25 1729-1735.
43. Sellers M, Beenken S, Blankenship A, Soong SJ, Turbat-Herrera E, Urist M & Maddox W 1992 Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. American Journal of Surgery 164 578-581.
44. Shattuck TM, Westra WH, Ladenson PW & Arnold A 2005 Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. New England Journal of Medicine 352 2406-2412.
45. Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB & Panzarella T 1987 Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. American Journal of Medicine 83 479-488.
46. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simoes M 2003 BRAF mutations RET/PTC rearrangements are alternative events in the etiopadiogenesis of PTC. Oncogene 22 4578-4580.
47. Strate SM, Lee EL & Childers JH 1984 Occult papillary carcinoma of the thyroid with distant metastases. Cancer 54 1093-1100.
48. Sugg SL, Ezzat S, Rosen IB, Freeman JL & Asa SL 1998 Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. Journal of Clinical Endocrinology and Metabolism 83 4116-4122.
49. Sugino K, Ito KJr, Ozaki O, Mimura T, Iwasaki H & Ito K 1998 Papillary microcarcinoma of the thyroid. Journal of Endocrinological Investigation 21 445-448.
50. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM et al. 2005 Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv 446 589-595.
51. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP & Parmentier C 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55 794-804.
52. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, Elisei R, Santoro M & Basolo F 2007 Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17 381-388.
53. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y & Uchida K 2004 Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clinical Cancer Research 10 2035-2043.
54. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH & Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. American Journal of Clinical Pathology 120 71-77.
55. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y & de la Chapelle A 2004 CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 14 169-175.
56. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A & Giordano C 2007 BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid < or = I cm and their paired lymph node metastases. Cancer 110 1218-1226.
57. Rodriguez JM, Moreno A, Parrilla P, Sola J, Soria T, Tebar FJ & Aranda F 1997 Papillary thyroid microcarcinoma: clinical study and prognosis. European Journal of Surgeyy 163 255-259.
58. Rosai J, LiVolsi VA, Sobrinho-Simoes M & Williams ED 2003 Renaming papillary microcarcinoma of the thyroid gland: the Porto proposal. International Journal of Surgical Pathology 11 249-251.
59. Sakorafas GH, Giotakis J & Stafyla V 2005 Papillary thyroid microcarcirroma: a surgical perspective. Cancer Treatment and Research 31 423-438.
60. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F et al. 2004 Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 89 5175-5180.
61. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, Lusbnikov E, Kumagai A, Nakashima M, Meirmanov S et al. 2004 The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. International Journal of Oncology 25 1729-1735.
62. Sellers M, Beenken S, Blankenship A, Soong SJ, Turbat-Herrera E, Urist M & Maddox W 1992 Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. American Journal of Surgery 164 578-581.
63. Shattuck TM, Westra WH, Ladenson PW & Arnold A 2005 Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. New England Journal of Medicine 352 2406-2412.
64. Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB & Panzarella T 1987 Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. American Journal of Medicine 83 479-488.
65. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simoes M 2003 BRAF mutations RET/PTC rearrangements are alternative events in the etiopadiogenesis of PTC. Oncogene 22 4578-4580.
66. Strate SM, Lee EL & Childers JH 1984 Occult papillary carcinoma of the thyroid with distant metastases. Cancer 54 1093-1100.
67. Sugg SL, Ezzat S, Rosen IB, Freeman JL & Asa SL 1998 Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. Journal of Clinical Endocrinology and Metabolism 83 4116-4122.
68. Sugino K, Ito K Jr, Ozaki O, Mimura T, Iwasaki H & Ito K 1998 Papillary microcarcirroma of the thyroid. Journal of Endocrinological Investigation 21 445-448.
69. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM et al. 2005 Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv 446 589-595.
70. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP & Parmentier C 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55 794-804.
71. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, Elisei R, Santoro M & Basolo F 2007 Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17 381-388.
72. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y & Uchida K 2004 Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clinical Cancer Research 10 2035-2043.
73. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH & Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence ofras mutations. American Journal of Clinical Pathology 120 71-77.